menu

Karel Petrak

New concepts in drug targeting

Awards earned

0

0

0

0

Level:

12 month points:

Total points:

Active Member
327
453
See More
  • Focus

    Contributions are valued by peers

  • Accountability

    Thoroughly contributes in all areas

  • Sense of Urgency

    Consistently responds in a timely fashion

  • Team

    Frequently supports and responds to peers

Skill demonstrated on Convetit

Energy Policy Design and Evaluation
Drug Development
Energy Accounting
Pharmaceutical Manufacturing
Supply Chain
Pharmaceutical Industry
Pharmacy Operations
Assay Development
Health Information Systems
Cancer
Healthcare Analytics
Oncology
Healthcare
Insurance
Pharmacy Benefit Management
MD
Allied Health
global energy
Energy
Climate Change
Pharmaceutical Development
Climate Change & Environmental Policy
pharma
Drug Delivery
Drug targeting
Developing drugs suitable for site-specific delivery
Problem Solving
Pre-clinical and clinical study design
Project development and management
Innovation
Knowledge Management
Leadership
Grant administration from project design to successful grant application
Healthcare Management
Strategic Planning
R&D
Quality Management
Translational Research
Lactoferrins & recombinant human lactoferrin
Characterization - chemical & physical: drugs, proteins, polymers
Biotechnology
Structure versus property relationship
Creative writing for success
Clinical Development
Start-ups
Biopharmaceuticals
Clinical Research
Lifesciences
GLP
Regulatory Affairs
Research
FDA
Strategy
Pharmaceutics
Drug Discovery
Clinical Trials
Vaccines
Immunology
Technology Transfer
21 CFR Part 11
GMP
Infectious Diseases
CRO
Genomics
Commercialization
Molecular Biology
Validation
menu Summary

Accomplishments:
- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.

- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.

- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.

- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.

- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.

Published over 100 scientific publications and patents.

Specialties: Project leadership and management in all aspects of drug research and development.

work Experience

Chief Scientific Officer

NangioTx

February 2016 - Present

CSO guiding the company towards a successful submission of an Investigational New Drug designation for the company's lead compound.

In addition, is available for consulting services in the area of drug development and drug delivery, with special emphasis on site-selective / targeted delivery, covering pre-clinical, clinical and product-development phases.

VP for R&D

Agennix Inc.

July 2000 - September 2010

Leading development of a new immunomodulating-protein product from preclinical to successful Phase 2 clinical study in adult and neonatal sepsis.

Director and Program Head

Gene Medicine

September 1994 - August 1999

Leading multidiscipline projects, in a matrix system, gene-therapy projects in a number of indications.

VP R&D

GeneRxPlus

September 1999 - September 2000

Leading gene-therapy product development to treat lung injury.

Research Area Head

Ciba-Geigy / Novartis

August 1985 - October 1993

Leading multidisciplinary projects in advanced drug delivery


Domains of experience:

Energy Policy Design and Evaluation
Drug Development
Energy Accounting
Pharmaceutical Manufacturing
Supply Chain
Pharmaceutical Industry
Pharmacy Operations
Assay Development
Health Information Systems
Cancer
Healthcare Analytics
Oncology
Healthcare
Insurance
Pharmacy Benefit Management
MD
Allied Health
global energy
Energy
Climate Change
Pharmaceutical Development
Climate Change & Environmental Policy
pharma
Drug Delivery
Drug targeting
Developing drugs suitable for site-specific delivery
Problem Solving
Pre-clinical and clinical study design
Project development and management
Innovation
Knowledge Management
Leadership
Grant administration from project design to successful grant application
Healthcare Management
Strategic Planning
R&D
Quality Management
Translational Research
Lactoferrins & recombinant human lactoferrin
Characterization - chemical & physical: drugs, proteins, polymers
Biotechnology
Structure versus property relationship
Creative writing for success
Clinical Development
Start-ups
Biopharmaceuticals
Clinical Research
Lifesciences
GLP
Regulatory Affairs
Research
FDA
Strategy
Pharmaceutics
Drug Discovery
Clinical Trials
Vaccines
Immunology
Technology Transfer
21 CFR Part 11
GMP
Infectious Diseases
CRO
Genomics
Commercialization
Molecular Biology
Validation
stars Convetit Experience

09/2016

Participated on a Sprint: "Top Trends in IoT for Pharmaceutical Supply Chain"

08/2016

Participated on a Sprint: "Top Trends in Immunotherapy"

07/2016

Participated on a Sprint: "Future Trends in Immuno-oncology: Implications for Manufacturing, Drug Administration, and Supply Chain." on

Immunology
Lifesciences
Pharmaceutical Industry
Supply Chain
drug manufacturing

Recent Open Forum Activity:

check_circle